Search results
Disease latency bias and the protective effect of metformin against age-related macular degeneration...
Nature· 3 days agoThere arises a spurious association between the older medication and absence of the condition causing symptoms. Metformin is an old medication, but it remains the first-line treatment ...
StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)
ETF DAILY NEWS· 1 day agoStockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report published on Friday morning. The firm issued a sell rating on the biopharmaceutical company ...
Clearside Biomedical stock target cut, maintains Buy rating By Investing.com
Investing.com· 15 hours agoOn Monday, Clearside Biomedical (NASDAQ:CLSD) saw its price target adjusted by H.C. Wainwright. The...
Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 266.7% in April
ETF DAILY NEWS· 2 days agoAkari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 2,200 shares, a growth ...
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results
Investing.com· 4 days agoThe therapy showed an average gain in visual acuity, contrasting with the typical loss experienced...
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
WRBL Columbus· 7 days agoFood and Drug Administration ("FDA") has now determined that its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome is entitled to a Priority ...
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
Zacks via Yahoo Finance· 7 days agoApellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus...
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
TipRanks via Yahoo Finance· 4 days agoRisk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $46.43 Average Target Price from Analysts
ETF DAILY NEWS· 3 days agoShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat ...
15 businesses coming soon, now open in Georgetown
Community Impact· 14 hours agoCheck out the businesses that have recently opened in Georgetown or are slated to come to the area over the next year.